MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -97.73 Million EUR | -156.56% |
| 2022 | 172.79 Million EUR | 196.43% |
| 2021 | -179.2 Million EUR | -240.29% |
| 2020 | 127.73 Million EUR | 229.19% |
| 2019 | -98.87 Million EUR | -79.98% |
| 2018 | -54.93 Million EUR | 12.83% |
| 2017 | -63.02 Million EUR | -14.63% |
| 2016 | -54.97 Million EUR | -339.77% |
| 2015 | 22.92 Million EUR | 2979.79% |
| 2014 | -796.23 Thousand EUR | -105.13% |
| 2013 | 15.51 Million EUR | 74.29% |
| 2012 | 8.9 Million EUR | -50.77% |
| 2011 | 18.08 Million EUR | -6.41% |
| 2010 | 19.32 Million EUR | 5.08% |
| 2009 | 18.39 Million EUR | -20.83% |
| 2008 | 23.23 Million EUR | -76.14% |
| 2007 | 97.34 Million EUR | 11.4% |
| 2006 | 87.37 Million EUR | 124.45% |
| 2005 | 38.92 Million EUR | 1087.44% |
| 2004 | 3.27 Million EUR | 435.75% |
| 2003 | -976.45 Thousand EUR | 95.83% |
| 2002 | -23.39 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -263.37 Million EUR | -1078.14% |
| 2023 Q1 | -13.95 Million EUR | -106.04% |
| 2023 Q4 | 26.92 Million EUR | 153.43% |
| 2023 Q3 | -50.4 Million EUR | -23.23% |
| 2023 FY | - EUR | -156.56% |
| 2023 Q2 | -40.9 Million EUR | -193.14% |
| 2022 Q3 | 43.9 Million EUR | 187.2% |
| 2022 Q4 | 230.96 Million EUR | 426.11% |
| 2022 Q1 | -59.6 Million EUR | 35.64% |
| 2022 FY | - EUR | 196.43% |
| 2022 Q2 | -50.34 Million EUR | 15.53% |
| 2021 Q2 | -71.6 Million EUR | -443.14% |
| 2021 FY | - EUR | -240.29% |
| 2021 Q3 | -78.9 Million EUR | -10.2% |
| 2021 Q1 | -13.18 Million EUR | 67.15% |
| 2021 Q4 | -92.6 Million EUR | -17.36% |
| 2020 Q1 | 226.01 Million EUR | 546.65% |
| 2020 Q4 | -40.12 Million EUR | -46.48% |
| 2020 Q3 | -27.39 Million EUR | 10.93% |
| 2020 FY | - EUR | 229.19% |
| 2020 Q2 | -30.75 Million EUR | -113.61% |
| 2019 Q4 | -50.6 Million EUR | -119.33% |
| 2019 Q1 | -21.11 Million EUR | 53.79% |
| 2019 Q2 | -4.09 Million EUR | 80.62% |
| 2019 FY | - EUR | -79.98% |
| 2019 Q3 | -23.07 Million EUR | -463.85% |
| 2018 Q1 | -18.03 Million EUR | -26.43% |
| 2018 Q4 | -45.68 Million EUR | -246.83% |
| 2018 Q2 | -22.92 Million EUR | -27.09% |
| 2018 FY | - EUR | 12.83% |
| 2018 Q3 | 31.11 Million EUR | 235.75% |
| 2017 Q1 | -13.82 Million EUR | 49.84% |
| 2017 FY | - EUR | -14.63% |
| 2017 Q4 | -14.26 Million EUR | 35.09% |
| 2017 Q3 | -21.97 Million EUR | -53.5% |
| 2017 Q2 | -14.31 Million EUR | -3.54% |
| 2016 Q2 | -8.21 Million EUR | 3.89% |
| 2016 FY | - EUR | -339.77% |
| 2016 Q4 | -27.56 Million EUR | -134.68% |
| 2016 Q3 | -11.74 Million EUR | -42.93% |
| 2016 Q1 | -8.55 Million EUR | 45.95% |
| 2015 Q4 | -15.82 Million EUR | -57.74% |
| 2015 FY | - EUR | 2979.79% |
| 2015 Q3 | -10.03 Million EUR | -71.73% |
| 2015 Q2 | -5.84 Million EUR | -110.44% |
| 2015 Q1 | 55.96 Million EUR | 5230.77% |
| 2014 Q1 | 2.76 Million EUR | 184.88% |
| 2014 FY | - EUR | -105.13% |
| 2014 Q4 | -1.09 Million EUR | 49.37% |
| 2014 Q3 | -2.15 Million EUR | -607.19% |
| 2014 Q2 | 424.8 Thousand EUR | -84.63% |
| 2013 Q4 | -3.25 Million EUR | -109.36% |
| 2013 Q2 | 16.47 Million EUR | 325.7% |
| 2013 FY | - EUR | 74.29% |
| 2013 Q1 | 3.87 Million EUR | -38.37% |
| 2013 Q3 | -1.55 Million EUR | -109.44% |
| 2012 Q1 | 918.21 Thousand EUR | 116.01% |
| 2012 Q2 | 941.67 Thousand EUR | 2.56% |
| 2012 Q3 | 1.23 Million EUR | 30.72% |
| 2012 Q4 | 6.28 Million EUR | 410.23% |
| 2012 FY | - EUR | -50.77% |
| 2011 Q1 | 29.4 Million EUR | 512.99% |
| 2011 FY | - EUR | -6.41% |
| 2011 Q2 | -4.04 Million EUR | -113.76% |
| 2011 Q4 | -5.73 Million EUR | -287.13% |
| 2011 Q3 | -1.48 Million EUR | 63.4% |
| 2010 Q4 | 4.79 Million EUR | 63.64% |
| 2010 FY | - EUR | 5.08% |
| 2010 Q1 | 6 Million EUR | 64.88% |
| 2010 Q2 | 5.58 Million EUR | -6.97% |
| 2010 Q3 | 2.93 Million EUR | -47.54% |
| 2009 Q3 | 4.44 Million EUR | 12.89% |
| 2009 Q4 | 3.64 Million EUR | -17.99% |
| 2009 FY | - EUR | -20.83% |
| 2009 Q2 | 3.93 Million EUR | -38.21% |
| 2009 Q1 | 6.36 Million EUR | 0.0% |
| 2008 FY | - EUR | -76.14% |
| 2007 FY | - EUR | 11.4% |
| 2006 FY | - EUR | 124.45% |
| 2005 FY | - EUR | 1087.44% |
| 2004 FY | - EUR | 435.75% |
| 2003 FY | - EUR | 95.83% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -37.59% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -1548.501% |
| SQZ Biotechnologies Company | -64.14 Million USD | -52.38% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -462.683% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 203.935% |
| Mesoblast Limited | -62.38 Million USD | -56.657% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -6262.956% |
| Genus plc | 73.7 Million USD | 232.616% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1378.301% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -2655.517% |
| Marizyme, Inc. | -34.28 Million USD | -185.105% |
| ContraFect Corporation | -64.99 Million USD | -50.369% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -1014.206% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -2059.388% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6872.29% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -3595.974% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -4105.925% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -18766.687% |
| Accustem Sciences Inc. | -3.74 Million USD | -2508.841% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -102.663% |
| EV Biologics, Inc. | -1.26 Million USD | -7613.333% |
| Q BioMed Inc. | -617.62 Thousand USD | -15724.755% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 2836.229% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -15354.963% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -4178.336% |
| Biomind Labs Inc. | -1.03 Million USD | -9347.413% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 1089.553% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1264.814% |
| Skye Bioscience, Inc. | -13.54 Million USD | -621.445% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -6471.018% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -390852.464% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -2416.222% |
| IMV Inc. | -35.52 Million USD | -175.137% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -515.877% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -3806.459% |
| GB Sciences, Inc. | -1.41 Million USD | -6783.523% |
| Alpha Cognition Inc. | -9.7 Million USD | -907.028% |
| HST Global, Inc. | -5303.00 USD | -1842972.148% |
| CSL Limited | 4.78 Billion USD | 102.041% |
| Halberd Corporation | -74.27 Thousand USD | -131482.434% |
| Enzolytics Inc. | -2.12 Million USD | -4505.88% |
| Resverlogix Corp. | -11.74 Million USD | -732.38% |
| Affymax, Inc. | -14.29 Million USD | -583.722% |
| SYBLEU INC | -141.57 Thousand USD | -68938.232% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -3090.911% |
| argenx SE | -216.02 Million USD | 54.756% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -76.617% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 8131.07% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -6420.63% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 25899.04% |
| AVAX Technologies, Inc. | -6.11 Million USD | -1498.95% |
| Zenith Capital Corp. | -8.6 Million USD | -1035.697% |
| Genscript Biotech Corporation | -248.71 Million USD | 60.703% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -560936.198% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -3895.082% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -55425.335% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -146.584% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -3279.222% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -9241.202% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1453671.029% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -5485.038% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -4988.113% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1193.92% |
| ONE Bio Corp. | 13.61 Million USD | 817.974% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -53872.718% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -4651.488% |
| Agentix Corp. | -1.37 Million USD | -7025.037% |
| LadRx Corporation | 412.28 Thousand USD | 23806.56% |
| Cell Source, Inc. | -4.27 Million USD | -2187.596% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -26515.612% |
| Regen BioPharma, Inc. | 1.46 Million USD | 6767.193% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -10331.53% |
| NovAccess Global Inc. | -1.03 Million USD | -9345.149% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1203.911% |
| Itoco Inc. | -1.86 Million USD | -5129.448% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -25646.303% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -8657.896% |
| Kadimastem Ltd | -2.62 Million USD | -3624.235% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -40768.959% |
| CytoDyn Inc. | -18.02 Million USD | -442.116% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -123573.735% |
| Mobile Lads Corp. | -2.24 Million USD | -4261.052% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -799132.284% |
| Qrons Inc. | -40.08 Thousand USD | -243751.491% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -20024.057% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 18630.906% |
| Rebus Holdings, Inc. | -951 Thousand USD | -10177.404% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -9103.126% |
| International Stem Cell Corporation | 202 Thousand USD | 48485.206% |
| Bioxytran, Inc. | -3.82 Million USD | -2458.491% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -185572.713% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -3869.976% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -172.486% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -217095.813% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -3469.69% |
| Neutra Corp. | -181.24 Thousand USD | -53825.37% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -384.836% |
| PureTech Health plc | -11.62 Million USD | -740.613% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -384.869% |
| IXICO plc | -707 Thousand USD | -13724.345% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1171.804% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -102.164% |
| CSL Limited | 4.73 Billion USD | 102.065% |
| Cellectis S.A. | -92.63 Million USD | -5.508% |